The UK based 20M series capital butcher tech crunch, also known as the capital butcher tech review, is an online newsletter dedicated to providing you with the latest information regarding various products and services from the UK. This includes Lub Foods, Beckley Psytech, Cleo, Glimpse Protocol, and more 52av.
Lub Foods
The FabFoods foodtech startup has announced a EUR20 million bridging funding round, which will fund the startup’s upcoming Series B. The company notes that the funds will be used to develop a platform that helps foodservice outlets track inventory and logistics. This round will also give the company equity, which it will use in the Series B.
One of the startups to come out of the recent Foodtech Crunch, Planted, is now working on expanding its reach to other European markets. Founded in Zurich, the company has already partnered with more than 3,000 restaurants and retail stores in three regional markets. Now it plans to expand to more than 4,200 retailers across Germany, Switzerland, Belgium, the Netherlands, and Luxembourg. Founder Nick Luthman, who is self-taught in food engineering, started the company after he was diagnosed with pre-diabetes. He followed a strict anti-inflammatory diet and learned all he could about nutrition. With his knowledge and passion for food, he helped create delicious treats without compromising on flavor.
Beckley Psytech
Beckley Psytech is a UK-based biotech start-up. Its aim is to develop innovative psychedelic medicines to treat patients with debilitating conditions. The company’s current pipeline includes two psychedelic compounds – BPL-003, a patented intranasal benzoate formulation of 5-MeO-DMT, and ELE-101, an intravenous formulation of psilocin. In addition, the company plans to develop other novel psychedelic compounds.
As part of its development, the company is also in the midst of a Phase 1b clinical trial on low-dose psilocybin. It plans to continue analysing data from the Phase 1b trial and applying these learnings to its pipeline of psychedelic compounds. During the study, patients will participate in psilocybin-assisted therapy – an approach where patients are under the guidance of a therapist and take psilocybin.
Finally
Beckley Psytech is also in the process of acquiring Eleusis Therapeutics Limited, a UK-based clinical-stage life sciences company. The acquisition is expected to immediately enhance the company’s clinical pipeline with the addition of the Eleusis research and development team. This new addition will help the company to better target the market for short-duration psychedelic therapies.
